← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Invesco Biotechnology & Genome ETF PBE $419M	86	+4	+5%	$121M
27	27 Atara Biotherapeutics ATRA $95.2M	85	-6	-7%	$509M
28	BLCM 28 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	81	-2	-2%	$333M
29	29 DELISTED Adverum Biotechnologies ADVM	76	-16	-17%	$153M
30	NSTG 30 DELISTED NanoString Technologies, Inc. NSTG	73	+11	+18%	$224M
31	SIOX 31 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	70	-1	-1%	$454M
32	32 Lineage Cell Therapeutics LCTX $248M	68	-6	-8%	$134M
33	33 Regenxbio RGNX $455M	66	+18	+38%	$247M
34	34 uniQure QURE $1.52B	64	+2	+3%	$136M
35	35 Veracyte VCYT $3.54B	64	+3	+5%	$110M
36	36 Rocket Pharmaceuticals RCKT $251M	60	+7	+13%	$218M
37	37 Fate Therapeutics FATE $223M	54	+10	+23%	$62.7M
38	38 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	52	+5	+11%	$22.9M
39	39 Arbutus Biopharma ABUS $836M	51	-4	-7%	$81.7M
40	ADAP 40 DELISTED Adaptimmune Therapeutics ADAP	49	+8	+20%	$250M
41	ATHX 41 DELISTED Athersys, Inc. Common Stock ATHX	49	+3	+7%	$7.54M
42	42 Cellectis CLLS $106M	48	+5	+12%	$219M
43	NVTA 43 DELISTED Invitae Corporation NVTA	48	-2	-4%	$164M
44	44 Abeona Therapeutics ABEO $255M	45	+2	+5%	$26M
45	45 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	44	+6	+16%	$518M
46	46 Fortress Biotech FBIO $63M	40	+1	+3%	$17.7M
47	47 Vericel Corp VCEL $2.05B	40	+3	+8%	$30.2M
48	48 Neurogene NGNE $473M	39	+6	+18%	$171M
49	49 Pluri PLUR $12.2M	37	+9	+32%	$6.76M
50	50 Voyager Therapeutics VYGR $124M	35	+35	–	$225M